Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Booth

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Biopharmaceutics & Drug Disposition|January 25, 2012
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceJoseph A Grillo, Ping Zhao, Julie Bullock, et al.
NPJ Vaccines|February 24, 2022
The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and EnglandJoshua Nealon, Daniel Modin, Rebecca E Ghosh, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 11, 2007
Myocilin Gly252Arg mutation and glaucoma of intermediate severity in Caucasian individualsAlex W Hewitt, Sonya L Bennett, Julia E Richards, et al.
Bioanalysis|November 19, 2010
2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group WorkshopNatasha Savoie, Fabio Garofolo, Peter van Amsterdam, et al.
Epilepsy Research|December 12, 2023
Personalization of SUDEP risk: A survey of transient subclinical comorbid changesKristina A Simeone, Dawn M Martenz, Shruthi H Iyer, et al.
Bioanalysis|November 19, 2010
The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysisNatasha Savoie, Brian P Booth, Troy Bradley, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 21, 2023
Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer NetworkJennifer P Booth, Julie M Kennerly-Shah, Lindsey R Kelley, et al.
Clinical Epidemiology|May 21, 2020
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European CountriesEdith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphomaBhupinder S Mann, John R Johnson, Kun He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Tristan Massie, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Biopharmaceutics & Drug Disposition|January 25, 2012
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceJoseph A Grillo, Ping Zhao, Julie Bullock, et al.
NPJ Vaccines|February 24, 2022
The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and EnglandJoshua Nealon, Daniel Modin, Rebecca E Ghosh, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|January 11, 2007
Myocilin Gly252Arg mutation and glaucoma of intermediate severity in Caucasian individualsAlex W Hewitt, Sonya L Bennett, Julia E Richards, et al.
Bioanalysis|November 19, 2010
2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group WorkshopNatasha Savoie, Fabio Garofolo, Peter van Amsterdam, et al.
Epilepsy Research|December 12, 2023
Personalization of SUDEP risk: A survey of transient subclinical comorbid changesKristina A Simeone, Dawn M Martenz, Shruthi H Iyer, et al.
Bioanalysis|November 19, 2010
The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysisNatasha Savoie, Brian P Booth, Troy Bradley, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 21, 2023
Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer NetworkJennifer P Booth, Julie M Kennerly-Shah, Lindsey R Kelley, et al.
Clinical Epidemiology|May 21, 2020
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European CountriesEdith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphomaBhupinder S Mann, John R Johnson, Kun He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphomaMartin H Cohen, John R Johnson, Tristan Massie, et al.
Pageof 15